Takara releases new line of beta cells for research

Takara Bio USA Inc. this week announced the launch of a new line of human induced pluripotent stem cell (hiPSC)-derived cells.

The fully differentiated Cellartis hiPS beta cells can be used for diabetes research and testing drugs.

"We have developed a standardized method that mimics embryonic development to manufacture industrial quantities of cryopreserved beta cells to be used for in vitro applications," Takara Bio Europe AB Head and Senior Director in Business Development Kristina Runeberg said.

The beta cells produce high amounts of insulin and C-peptides. The reduced variability from batch to batch of the cells allows researchers to find consistent results in research on diabetes and beta cell functions.

"We are committed to providing stem cell researchers with the highest quality tools and services to address current roadblocks in research and drug discovery," Takara Bio USA President Carol Lou said. "With more than 15 years of experience in pluripotent stem cell generation and differentiation, our scientists are well-positioned to develop the types of products needed to support significant advances in stem cell research. As a new addition to our stem cell portfolio, which includes our DEF-CS culture system for research- and clinical-grade expansion of hiPS cells, Cellartis hiPS beta cells provide a focused solution for the study of diabetes and other pancreatic disorders."